The Top Five Product Searches on CPHI Online: December
Which were the products that drew the most interest in the CPHI directory in December? We analyse search data from the CPHI directory…
1. Avoquin 4% - Avalon Pharma
Retaining its position at the top of the tree during the previous month, this skin lightening cream continues to attract the most interest on CPHI Online.
The formulation – sold in African, Middle Eastern and Asian markets -- contains hydroquinone, which the company describes as the ‘gold standard’ for treatment of skin hyperpigmentation and claims has been proven in clinical trials to be the safest and most effective skin lightening agent.
Skin lightening refers to the practice of using chemical substances to lighten the skin or provide an even skin colour by reducing the melanin concentration. Hydroquinone is currently not approved for this purpose in Europe.
2. Avocom-M cream – Avalon Pharma
This anti-inflammatory, antipruritic and anti-allergic cream, also from Avalon Pharma, crept up one place in December. The product is a unique combination of corticosteroid, Mometasone Furoate, (0.1% concentration) and anti-fungal Miconazole Nitrate (2%).
3. Avalon Avotin -Avalon Pharma
Last month, Avalon recorded three products in the top five; this month the young Saudi Arabian company has matched that, with the added bonus of them occupying all three podium positions. This formulation of Tretinoin cream, a derivative of vitamin A, was a new entry in December. It is a versatile retinoid that works by increasing the growth rate of skin cells and is used to treat a variety of skin conditions, from acne to aging.
4. Spasmo-Apotel (Paracetamol + Hyoscine Butylbromide) – Uni-Pharma
The month’s second new entrant comes from Greece’s Uni-Pharma and is a combination of hyoscine hydrobromide, taken to relieve stomach cramps, including those linked with irritable bowel syndrome, and painkiller, paracetamol.
5. Mycoten - Munir Sukhtian Group
Rounding off, the top five, this antifungal treatment slipped down three places from second position in November. The formulation, available in both tablets and cream, contains the active ingredient clotrimazole and is used for the relief of vaginal itching, burning, and discharge associated with vaginal yeast infections (vulvovaginal candidiasis).
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US
The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta... -
News A Day in the Life of a Director of Business Development
In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global... -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.